Extended Data Table 1.

Antigen discovery strategies in neuroblastoma

a. Annotation of CDX (cell line derived xenograft), PDX (patient derived xenograft), and high-risk primary patient tumors selected for immunopeptidomics. Age in years. Stage 4 = metastatic at diagnosis, Stage 3 = large unresectable primary tumor but no hematogenous metastases. Protein coding mutations in known neuroblastoma oncogenes. b. Peptides derived from CRC genes detected in neuroblastoma immunopeptidome. High confidence indicates spectra were detected in multiple replicates and possess high coverage across b and y ions. Spectra containing peptides from ASCL1, HAND2, and ISL1 were observed in at least one replicate and/or with partial coverage across B and Y ions, necessitating further validation to confirm presentation of peptides.